I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

Contrast-induced acute kidney injury (CIAKI), which is characterized by the development of acute renal insufficiency after exposure to a radiocontrast agent, is a major complication that has adverse outcomes after contrast medium injections.\[[@ref1]\] Although CIAKI is generally transient and clinically asymptomatic, it is associated with prolonged hospital stays, increased health care costs and higher mortality rates, particularly in patients with diabetes and/or chronic kidney disease (CKD).\[[@ref2][@ref3][@ref4]\]

In the multicenter, randomized TRACK-D trial,\[[@ref5]\] we have demonstrated the safety and efficacy of short-term rosuvastatin in preventing CIAKI in patients with moderate or severe CKD and diabetes, which was consistent with the results of several recently published randomized trials.\[[@ref6][@ref7][@ref8][@ref9]\] Due to the different inclusion criteria, the mean contrast volumes varied in previous studies. Given that contrast volume is an independent predictor of CIAKI,\[[@ref10]\] it is important to know if the efficacy of statin in CIAKI prevention is consistent across different stratifications of contrast volume. In this prespecified analysis of the TRACK-D trial, we sought to explore the efficacy of short-term rosuvastatin treatment in preventing CIAKI in patients with contrast administration ≥200 ml.

M[ETHODS]{.smallcaps} {#sec1-2}
=====================

Study population {#sec2-1}
----------------

The TRACK-D trial design has been previously described in detail.\[[@ref5]\] Briefly, this investigator-initiated, prospective, randomized controlled trial enrolled patients with type 2 diabetes mellitus (DM) and Stage 2 or 3 CKD undergoing coronary/peripheral arterial diagnostic angiography, left ventriculography, or percutaneous coronary intervention (PCI) at 53 Chinese centers. The primary exclusion criteria were hypersensitivity to contrast medium or statins, type 1 DM, ketoacidosis, lactic acidosis, Stage 0 or 1 CKD, Stage 4 or 5 CKD, acute ST-segment elevation myocardial infarction within the previous 4 weeks, Class IV heart failure (as defined by the New York Heart Association \[NYHA\] functional classification system), hemodynamic instability, administration of iodinated contrast medium during the 2 weeks before randomization, low-density lipoprotein cholesterol (LDL-C) concentration \<1.82 mmol/L, and hepatic dysfunction or renal artery stenosis (unilateral \>70% or bilateral \>50%). All patients provided written, informed consent before study enrollment, and the study was approved by the Ethics Committees at all participating centers.

Study treatment {#sec2-2}
---------------

Patients were randomized to treatment with either rosuvastatin (Crestor; Astra Zeneca, UK), 10 mg every evening or blank control from 2 days before to 3 days after contrast medium administration. Statin therapy was resumed in both groups 3 days after contrast medium administration. Hydration therapy was administered at the physicians' discretion. The iso-osmolar, nonionic contrast medium iodixanol (Visipaque, GE Healthcare) was administered during all procedures.

Study outcomes {#sec2-3}
--------------

The primary outcome was the development of CIAKI, which was defined as an increase in serum creatinine concentration ≥0.5 mg/dl (44.2 mmol/L) or ≥25% above baseline at 72 h after exposure to the contrast medium. The secondary outcome was a composite of adverse clinical events at 30 days after exposure to the contrast medium, including all-cause death, dialysis/hemofiltration or worsening heart failure, which was defined as a deteriorated NYHA functional class (i.e. a class change ≥1).

Statistical analysis {#sec2-4}
--------------------

Analyses were performed based on the modified intention-to-treat population, which was defined as all patients who underwent randomization and had at least one assessment of renal function after being administered the contrast medium. Comparisons among normally distributed continuous variables, which were expressed as the means ± standard deviation, were performed using *t*-tests. The Chi-squared test or the Fisher\'s exact test was used for the categorical data, which were expressed as percentages. Time-to-events curves were calculated using the Kaplan--Meier method and compared with log-rank tests. All *P* values were two-tailed, and statistical significance was defined as a *P* ≤ 0.05. All statistical analyses were performed using SAS software, version 9.13 (SAS Institute Inc., Cary, NY, USA).

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

Patients {#sec2-5}
--------

Of the 2998 patients included in the TRACK-D study, 932 (31.1%) were administered a contrast medium volume ≥200 ml. These patients were stratified into two groups: The moderate contrast volume group (MCV, 200--300 ml, *n* = 712) and the high contrast volume (HCV) group (HCV, ≥300 ml, *n* = 220). In the MCV group, 357 (52.7%) patients were allocated in the rosuvastatin arm, and 355 (47.3%) were allocated in the control arm. For the HCV patients, 118 (53.6%) were allocated in the rosuvastatin arm, and 102 (46.4%) were allocated in the control arm. Baseline clinical characteristics, procedural results, and in-hospital medications were comparable between the rosuvastatin and control groups in both patient stratifications, as shown in [Table 1](#T1){ref-type="table"}.

###### 

Baseline characteristics

  Parameters                           Moderate contrast volume (*n* = 712)   High contrast volume (*n* = 220)                                         
  ------------------------------------ -------------------------------------- ---------------------------------- ------- -------------- -------------- -------
  Age (years)                          61.8 ± 8.5                             61.4 ± 8.7                         0.907   61.0 ± 9.2     61.5 ± 8.1     0.571
  Men, *n* (%)                         244 (68.3)                             263 (74.1)                         0.091   87 (73.7)      76 (74.5)      0.895
  Risk factors, *n* (%)                                                                                                                                
   Body mass index                     25.5 ± 2.9                             25.5 ± 2.8                         0.732   25.6 ± 2.9     26.1 ± 2.5     0.384
   Current smoker                      114 (31.9)                             122 (34.4)                         0.383   41 (34.7)      43 (42.2)      0.269
  Diabetes history, *n* (%)                                                                                                                            
   \<5 years                           187 (52.4)                             197 (55.5)                         0.598   60 (50.8)      48 (47.1)      0.507
   5--10 years                         71 (19.9)                              71 (20.0)                                  27 (22.9)      20 (19.6)      
   ≥10 years                           99 (27.7)                              87 (24.5)                                  31 (26.3)      34 (33.3)      
  Hypertension, *n* (%)                255 (71.4)                             270 (76.1)                         0.247   96 (81.4)      73 (71.6)      0.086
  Prior MI, *n* (%)                    92 (25.8)                              74 (20.8)                          0.120   33 (28.0)      25 (24.5)      0.562
  CAD family history, *n* (%)          21 (5.9)                               18 (5.1)                           0.634   8 (6.8)        6 (5.9)        0.786
  Hypercholesteremia, *n* (%)          28 (7.8)                               21 (5.9)                           0.310   7 (5.9)        2 (2.0)        0.138
  Hypertriglyceridemia, *n* (%)        35 (9.8)                               30 (8.5)                           0.531   13 (11.0)      8 (7.8)        0.424
  Clinical presentation                                                                                                                                
   Acute coronary syndromes, *n* (%)   304 (85.2)                             300 (84.7)                         0.810   102 (86.4)     87 (85.3)      0.807
   SBP, mm Hg                          138.8 ± 20.8                           140.9 ± 21.2                       0.561   143.3 ± 20.1   144.0 ± 26.1   0.206
   DBP, mm Hg                          81.2 ± 13.0                            81.7 ± 13.7                        0.861   85.0 ± 12.7    83.3 ± 14.4    0.383
  NYHA class, *n* (%)                                                                                                                                  
   Class I                             292 (81.8)                             290 (81.7)                         0.852   101 (85.6)     86 (84.3)      0.593
   Class II                            59 (16.5)                              57 (16.1)                                  16 (13.6)      16 (15.7)      
   Class III                           6 (1.7)                                8 (2.3)                                    1 (0.8)        0 (0)          
  Ejection fraction, %                 62.1 ± 8.8                             62.4 ± 8.0                         0.095   61.9 ± 8.8     62.1 ± 8.7     0.859
  Procedural results                                                                                                                                   
   Diseased vessel number, *n* (%)                                                                                                                     
    0                                  5 (1.4)                                10 (2.8)                           0.254   3 (2.5)        2 (2.0)        0.880
    1                                  60 (16.8)                              69 (19.4)                                  16 (13.6)      12 (11.8)      
    ≥2                                 292 (81.8)                             276 (77.7)                                 99 (83.9)      88 (86.3)      
   PCI, *n* (%)                        328 (91.9)                             317 (89.3)                         0.238   102 (86.4)     90 (88.2)      0.690
   Contrast volume, ml                 212.1 ± 22.6                           210.7 ± 22.1                       0.210   347.2 ± 86.1   343.2 ± 67.3   0.336
  Medications, *n* (%)                                                                                                                                 
   ACEI                                241 (67.5)                             223 (62.8)                         0.189   88 (74.6)      69 (67.6)      0.257
   ARB                                 83 (23.2)                              87 (24.5)                          0.694   18 (15.3)      29 (28.4)      0.041
   Antibiotic                          78 (21.8)                              65 (18.3)                          0.239   33 (28.0)      18 (17.6)      0.070
   Insulin                             125 (35.0)                             118 (33.2)                         0.618   38 (32.2)      40 (35.71)     0.574
   Diuretic                            78 (21.8)                              71 (20.0)                          0.544   28 (23.7)      23 (22.5)      0.836
   Calcium antagonist                  136 (38.1)                             137 (38.6)                         0.892   55 (46.6)      46 (45.1)      0.822
   β-bloker                            291 (81.5)                             286 (80.6)                         0.747   100 (84.7)     84 (82.4)      0.632
   Heparin                             260 (72.8)                             277 (78.0)                         0.107   92 (78.0)      88 (86.3)      0.111
   Digitalis                           38 (10.6)                              33 (9.3)                           0.548   12 (10.2)      12 (11.8)      0.705
   Hydration                           189 (52.9)                             190 (53.5)                         0.877   77 (65.3)      65 (63.7)      0.813

Data were expressed as *n* (%) or mean ± SD. MI: Myocardial infarction; CAD: Coronary artery disease; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; NYHA: New York Heart Association; PCI: Percutanenous coronary intervention; ACEI: Angiotensin converting enzyme inhibitor; ARB: Angiotensin receptor II blocker; SD: Standard deviation.

Laboratory test results {#sec2-6}
-----------------------

Baseline and postprocedural serum creatinine concentrations were comparable between the rosuvastatin and control groups. Rosuvastatin treatment was associated with significant decreases in serum LDL-C and high sensitive C-reactive protein (hsCRP) compared to the control groups in both stratifications \[[Table 2](#T2){ref-type="table"}\].

###### 

Laboratory results

  Parameters                      Moderate contrast volume (*n* = 712)   High contrast volume (*n* = 220)                                         
  ------------------------------- -------------------------------------- ---------------------------------- ------- -------------- -------------- -------
  Serum creatinine, μmol/L                                                                                                                        
   Baseline                       92.9 ± 20.1                            94.1 ± 19.3                        0.897   92.9 ± 18.9    95.8 ± 19.8    0.832
   Day 2 postprocedure            93.4 ± 24.1                            95.4 ± 26.7                        0.498   93.3 ± 23.9    94.3 ± 20.2    0.411
   Day 3 postprocedure            92.2 ± 23.5                            95.8 ± 32.8                        0.168   92.9 ± 23.1    94.6 ± 19.4    0.188
  eGFR, ml/min                                                                                                                                    
   Baseline                       76.8 ± 15.7                            76.6 ± 16.2                        0.809   79.3 ± 21.4    75.4 ± 17.6    0.598
   Day 2 postprocedure            77.5 ± 19.0                            77.3 ± 22.0                        0.766   79.5 ± 21.4    77.3 ± 18.5    0.535
   Day 3 postprocedure            78.4 ± 18.6                            77.2 ± 20.0                        0.809   80.4 ± 22.3    77.2 ± 18.2    0.307
  Hemoglobin, g/dl                135.2 ± 14.9                           135.0 ± 14.7                       0.684   139.5 ± 17.6   134.8 ± 15.1   0.246
  WBC count, 10^9^                6.9 ± 1.7                              6.9 ± 2.0                          0.213   6.8 ± 1.8      7.3 ± 2.1      0.104
  Platelet count, 10^9^           194.0 ± 51.5                           198.2 ± 49.7                       0.734   205.3 ± 57.4   200.3 ± 42.7   0.066
  Fasting blood glucose, mmol/L                                                                                                                   
   Baseline                       7.6 ± 2.9                              7.6 ± 2.8                          0.345   7.7 ± 3.4      7.4 ± 3.3      0.580
   Day 3 postprocedure            7.2 ± 2.5                              7.2 ± 2.9                          0.874   7.0 ± 1.8      7.3 ± 2.7      0.074
  Total cholesterol, mg/dl                                                                                                                        
   Baseline                       4.7 ± 1.2                              4.6 ± 1.2                          0.405   4.7 ± 1.4      4.7 ± 1.3      0.293
   Day 3 postprocedure            3.9 ± 1.0                              4.8 ± 1.1                          0.038   3.9 ± 1.2      4.7 ± 1.0      0.012
  HDL-c, mg/dl                                                                                                                                    
   Baseline                       1.2 ± 0.4                              1.3 ± 0.7                          0.075   1.3 ± 0.8      1.3 ± 0.4      0.715
   Day 3 postprocedure            1.2 ± 0.3                              1.3 ± 0.5                          0.398   1.2 ± 0.3      1.3 ± 0.7      0.414
  LDL-c, mg/dl                                                                                                                                    
   Baseline                       2.6 ± 0.9                              2.5 ± 0.7                          0.135   2.6 ± 0.9      2.6 ± 0.7      0.199
   Day 3 postprocedure            2.1 ± 0.7                              2.6 ± 0.6                          0.019   2.1 ± 0.6      2.5 ± 0.7      0.022
  hsCRP, mg/L                                                                                                                                     
   Baseline                       1.7 ± 4.0                              1.8 ± 8.3                          0.358   1.9 ± 4.3      1.8 ± 1.2      0.310
   Day 3 postprocedure            1.4 ± 4.0                              1.7 ± 2.3                          0.005   1.3 ± 3.0      2.1 ± 3.1      0.016

Data were expressed as mean±SD. eGFR: Estimated glomerular filtration rate; WBC: White blood cell; HDL: High density lipoprotein; LDL: Low density lipoprotein; hsCRP: High sensitive C-reactive protein; SD: Standard deviation.

Clinical outcomes {#sec2-7}
-----------------

The incidence of CIAKI in the rosuvastatin treated patients was significantly lower than that of patients in the control group (2.1% vs. 4.4%, *P* = 0.050). For the MCV patients, short-term rosuvastatin treatment was associated with a significantly lower incidence of CIAKI compared to the controls (1.7% vs. 4.5%, relative risk \[*RR*\]: 0.373, 95% confidence interval \[*CI*\]: 0.148--0.942, *P* = 0.029). However, the benefit of rosuvastatin was not observed in the HCV patients (3.4% vs. 3.9%, *RR*: 0.949, 95% *CI*: 0.243--3.704, *P* = 0.834).

The incidence of secondary outcomes was significantly lower in the rosuvastatin group compared with the control group (2.7% vs. 5.3%, *P* = 0.049) in the overall cohort, but the incidence was similar between the groups of MCV patients (2.0% vs. 4.2%, *RR*: 0.464, 95% *CI*: 0.192--1.124, *P* = 0.081) or HCV patients (5.1% vs. 8.8%, *RR*: 0.576, 95% *CI*: 0.212--1.564, *P* = 0.273).

There were no interactions between the rosuvastatin treatment and contrast volume stratifications in terms of primary and secondary outcomes \[[Table 3](#T3){ref-type="table"}\].

###### 

Primary and secondary outcomes for different contrast volume stratifications

  Parameters          Rosuvastatin (*n* = 475)   Control (*n* = 457)   *P*     *P* for interaction
  ------------------- -------------------------- --------------------- ------- ---------------------
  Primary outcome                                                              
   Overall            10 (2.1)                   20 (4.4)              0.050   0.319
   MCV (*n* = 712)    6 (1.7)                    16 (4.5)              0.029   
   HCV (*n* = 220)    4 (3.4)                    4 (3.9)               0.834   
  Secondary outcome                                                            
   Overall            13 (2.7)                   24 (5.3)              0.049   0.780
   MCV (*n* = 712)    7 (2.0)                    15 (4.2)              0.081   
   HCV (*n* = 220)    6 (5.1)                    9 (8.8)               0.273   

Data were expressed as *n* (%). MCV: Moderate contrast volume; HCV: High contrast volume.

Time-to-event curves showed that rosuvastatin was associated with a nonsignificant reduction in the number of adverse clinical events in both the MCV \[[Figure 1a](#F1){ref-type="fig"}\] and HCV \[[Figure 1b](#F1){ref-type="fig"}\] stratifications.

![Time-to-event curves comparing adverse clinical events, a composite of death, dialysis/hemofiltration or worsened heart failure between the rosuvastatin and control groups of patients with moderate (a) and high volumes (b) of contrast medium administration.](CMJ-128-784-g001){#F1}

D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

TRACK-D trial was the first large randomized, multicenter, prospective study to evaluate the safety and efficacy of statin therapy in preventing CIAKI in diabetic patients with mild-to-moderate CKD. In this prespecified analysis of TRACK-D trial, we found that periprocedural administration of rosuvastatin (i.e. 10 mg daily for a short duration of 5 days) reduced the incidence of CIAKI in patients with type 2 diabetes and CKD who received moderate or high volumes (≥200 ml) of contrast administration, particularly in the MCV (200--300 ml) stratification.

Contrast-induced acute kidney injury, which is characterized by the development of acute renal insufficiency after exposure to radiocontrast, is the third leading cause of hospital-acquired acute renal injury, accounting for approximately 11% of all cases.\[[@ref11]\] Although CIAKI is generally benign in most instances, it is associated with lengthened hospital stays, increased health care costs, and increased risk of death.\[[@ref2][@ref3][@ref4]\] CIAKI greatly decreases the efficacy of PCI and results in adverse short- and long-term outcomes.

Several strategies, including hydration, using iso-osmolar contrast, and limiting the amount of administered contrast volume, have become well-established methods of preventing CIAKI. In recent years, periprocedural short-term statin treatment has been emerged as a novel strategy for preventing CIAKI. Several studies have reported that statins may be effective in preventing CIAKI. However, the results from early studies have varied,\[[@ref7][@ref8][@ref9][@ref12][@ref13][@ref14]\] primarily because of underpowered sample sizes or nonrandomized study designs. The TRACK-D study and simultaneously published PRATO-ACS study, both of which were well designed randomized trials, demonstrated that short-term rosuvastatin therapy is effective in preventing CIAKI and that the effects are consistent across all prespecified subgroups.\[[@ref5][@ref6]\] Based on this new evidence, statins treatment was recommended as a useful prophylactic measure for CIAKI in the updated European Society of Cardiology/European Association for Cardio-thoracic Surgery guidelines for myocardial revascularization.\[[@ref15]\]

The mechanism of statin in CIAKI prevention remains unknown. In the present study, patients who developed CIAKI had higher postprocedural hsCRP levels, and the preventive effect of rosuvastatin on CIAKI development was accompanied by a significant decrease in postprocedural hsCRP levels. Inflammation may contribute to the pathogenesis of CIAKI, and renal protection by rosuvastatin during exposure to contrast medium could be due to attenuation of inflammatory responses, a phenomenon observed in the JUPITER trial.\[[@ref16]\] In addition to their intended impact on blood cholesterol levels, statins have been found to have multiple nonlipid-lowering effects, which include enhancements of endothelial nitric oxide production, anti-inflammatory and anti-oxidative actions.\[[@ref17]\] Given their pleiotropic effects, statins could decrease acute renal injury after contrast administration through two major pathways. First, statins may modulate the kidney hypoperfusion after contrast administration by downregulating angiotensin receptors and decreasing synthesis of endothelin-1.\[[@ref18][@ref19]\] Therefore, these drugs may prevent CIAKI by decreasing the period of renal hypoperfusion and ischemia. Second, toxic damage to tubular cells by oxygen-free radicals and pro-inflammatory cytokines, with subsequent cytoplasmic vacuolization, necrosis, interstitial inflammation, and tubular obstruction by protein precipitates, may be decreased by the anti-inflammatory effects of statins, which inhibit tissue factor expression by macrophages and prevent the activation of nuclear factor-kB,\[[@ref20]\] a transcription factor that acts on genes encoding for pro-inflammatory mediators, availability, attenuating production of reactive oxygen species, decreasing expression of endothelial adhesion molecules, increasing nitric oxide bioavailability, attenuating production of reactive oxygen species.

Increased contrast medium administration, which is common in complex PCI procedures, is an independent predictor of CIAKI.\[[@ref10][@ref21]\] Hydration is an effective strategy to attenuate the adverse effects caused by contrast medium.\[[@ref15]\] However, in patients with heart failure or renal insufficiency, hydration should be carefully used. The results from the present study showed that short-term periprocedural rosuvastatin treatment was associated with a significant reduction in CIAKI and adverse clinical events for patients who received moderate or high volumes (≥200 ml) of contrast. Although the benefit of rosuvastatin was obvious in the patients who received moderate volumes of contrast (200--300 ml), there was no interaction between statin treatment and contrast volume stratifications, which indicated the consistent effects of rosuvastatin in both contrast volume stratifications. The less beneficial effects of rosuvastatin observed in patients who received high volume contrast administration (≥300 ml) might be attributed to the small sample size and low rosuvastatin dose (10 mg/day).

The present study had several limitations. First, the data presented in this study were derived from a prespecified but postrandomized analysis. Although the baseline characteristics were well matched between the two arms, interpretations of the results should be cautious due to the potential bias caused by the underpowered sample size and nonstratified randomization. Second, the definitions of moderate or HCV were determined by the investigators, but these definitions were not based on the receiver operating characteristics curve analysis. Thus, these definitions might not reflect the real risk of CIAKI and the procedural complexities.

In conclusion, periprocedural short-term rosuvastatin treatment is effective in reducing CIAKI and adverse clinical events for patients with diabetes and CKD after their exposure to moderate volumes of contrast medium during coronary/peripheral arterial angiography or percutaneous intervention.
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